Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3713705 | 0.80 | HTT (0.38) | PKMHTTSMN1; SMN2MAPTPOLB | |
| SCHEMBL670394 | 0.77 | — | — | |
| SCHEMBL30895742 | 0.77 | — | — | |
| SCHEMBL23963738 | 0.77 | CASP3 (0.35) | PKMHTTSMN1; SMN2MAPTPOLB | |
| SCHEMBL1502596 | 0.75 | KMT2A (0.57) | PKMHTTSMN1; SMN2MAPTPOLB | |
| SCHEMBL1502754 | 0.75 | CASP3 (0.42) | PKMHTTSMN1; SMN2MAPTPOLB | |
| SCHEMBL21535264 | 0.74 | PKM (0.40) | PKMHTTSMN1; SMN2MAPTPOLB | |
| SCHEMBL17048233 | 0.74 | HTT (0.42) | PKMHTTSMN1; SMN2MAPTPOLB | |
| SCHEMBL10682400 | 0.73 | HTT (0.43) | PKMHTTSMN1; SMN2MAPTPOLB | |
| SCHEMBL31614849 | 0.73 | CYP11B1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3124475-B1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-2701512-B1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2701512-B1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-3124475-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-02-01 | — | — | EP | disclosed |
| US-9073929-B2 | Aldosterone synthase inhibitors | ELEXOPHARM GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073929-B2 | Aldosterone synthase inhibitors | ELEXOPHARM GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| US-9073929-B2 | Aldosterone synthase inhibitors | ELEXOPHARM GMBH (DE) | 2015-07-07 | — | — | US | disclosed |
| EP-2701512-A1 | ALDOSTERONE SYNTHASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | ELEXOPHARM GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| WO-2012148808-A1 | ALDOSTERONE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045819-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP17A1, HSD11B1 | PKM 1389/4885HTT 4672/4885SMN1; SMN2 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.